Global Human Papillomavirus (HPV) Testing Market Size By Type (Pap Smear Test, HPV DNA Test), By Application (Diagnostic Centers, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Human Papillomavirus (HPV) Testing Market was valued at USD 3.4 billion in 2023 and is projected to reach USD 6.1 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. This market is being driven by the increasing prevalence of cervical cancer, growing awareness about early screening, and the integration of advanced molecular diagnostics in clinical workflows. HPV testing plays a crucial role in the early detection of high-risk HPV strains responsible for cervical cancer, prompting public health initiatives and routine screening programs globally. Technological advancements in PCR and next-generation sequencing (NGS) are further boosting adoption across clinical and diagnostic laboratories.

Drivers:

1. Rising Prevalence of Cervical Cancer:

The increasing incidence of HPV-associated cervical and other genital cancers is significantly driving the demand for regular and reliable HPV testing. WHO-led campaigns to eliminate cervical cancer and national screening guidelines in developed and emerging economies are reinforcing market growth.

2. Technological Advancements in Molecular Diagnostics:

Innovations in HPV detection technologies, including DNA and RNA-based assays, co-testing models (HPV + Pap), and fully automated platforms, are enhancing diagnostic accuracy and efficiency, encouraging broader clinical adoption.

3. Expansion of Screening Programs and Awareness Campaigns:

Growing investments in public health awareness campaigns and inclusion of HPV testing in routine check-ups are widening the market’s reach. Government-led initiatives in countries like Australia, the UK, and India are promoting early detection and vaccination.

Restraints:

1. High Cost of Advanced HPV Tests:

Although highly accurate, molecular HPV tests such as mRNA-based diagnostics can be expensive for routine screening, especially in low-income countries lacking reimbursement frameworks.

2. Limited Access in Low-resource Settings:

Infrastructure challenges and insufficient healthcare resources in remote and underdeveloped regions hinder the implementation of widespread HPV screening programs.

Opportunity:

1. Integration with Home-based and Point-of-care Testing Solutions:

The development of self-sampling kits and point-of-care (POC) diagnostics is transforming HPV screening accessibility. These innovations support privacy, reduce logistical barriers, and are gaining traction in community healthcare models.

2. Untapped Potential in Emerging Economies:

Countries in Asia-Pacific, Latin America, and Africa represent significant growth opportunities due to increasing healthcare investments, growing awareness of HPV-related diseases, and the introduction of government-sponsored screening initiatives.

3. Transition to Primary HPV Screening:

The global trend toward primary HPV screening (versus cytology-based methods) as the first-line test is accelerating market expansion and creating demand for robust diagnostic platforms.

Market by System Type Insights:

Based on system type, DNA-based HPV testing accounted for the largest market share in 2023. DNA-based tests are widely adopted due to their high sensitivity and ability to detect multiple high-risk HPV genotypes. Meanwhile, RNA-based testing is expected to witness the fastest growth due to its enhanced specificity, reducing unnecessary colposcopies and overdiagnosis.

Market by End-use Insights:

In terms of end use, Hospitals and Diagnostic Laboratories dominated the market in 2023, representing over 60% of the global revenue share. These settings provide the infrastructure necessary for accurate sample collection and advanced testing. Home care and self-sampling segments are rapidly emerging, particularly in urban areas where convenience and privacy are prioritized.

Market by Regional Insights:

Geographically, North America led the global HPV testing market in 2023, driven by favorable reimbursement policies, a high level of awareness, and the presence of major diagnostics companies. Asia-Pacific is projected to exhibit the highest CAGR during the forecast period, supported by government screening initiatives in China, India, and Southeast Asia, along with growing adoption of molecular diagnostics in urban healthcare centers.

Competitive Scenario:

Key players in the global HPV testing market include Roche Diagnostics, Abbott Laboratories, Hologic Inc., Qiagen N.V., Becton Dickinson and Company, Seegene Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, BioMérieux, and Danaher Corporation. These companies are actively investing in next-generation testing platforms, self-sampling kits, and strategic partnerships to enhance their global footprint.

Recent Developments:

In 2023, Roche launched a next-generation HPV DNA test with full genotype profiling for use in cervical cancer screening programs.

In 2024, Hologic partnered with a global health NGO to provide HPV self-sampling kits in rural parts of Southeast Asia.

Abbott Laboratories received FDA approval for its RNA-based HPV test for high-risk HPV detection in 2022.

Scope of Work – Global Human Papillomavirus (HPV) Testing Market

Report Metric Details

Market Size (2023) USD 3.4 billion

Projected Market Size (2031) USD 6.1 billion

CAGR (2023–2031) 7.5%

Market Segments By System Type (DNA-based, RNA-based), By End-use (Hospitals, Labs, Home)

Growth Drivers Rising cervical cancer prevalence, adoption of molecular diagnostics

Opportunities Self-sampling kits, emerging market expansion, transition to primary testing

Key Market Developments:

2023: Roche launched HPV full-genotype DNA tests supporting national cervical cancer screening programs.

2024: Qiagen introduced a CE-marked RNA-based HPV diagnostic kit with higher specificity.

2025: Thermo Fisher partnered with diagnostic labs in India to roll out HPV self-sampling devices.

FAQs:

1. What is the current market size of the Global Human Papillomavirus (HPV) Testing Market?

The market was valued at USD 3.4 billion in 2023.

2. What is the major growth driver of the Global Human Papillomavirus (HPV) Testing Market?

The major driver is the rising prevalence of cervical cancer and growing awareness of early HPV screening.

3. Which is the largest region during the forecast period in the Global Human Papillomavirus (HPV) Testing Market?

North America is expected to remain the largest region during the forecast period.

4. Which segment accounted for the largest market share in the Global Human Papillomavirus (HPV) Testing Market?

The DNA-based HPV testing segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Human Papillomavirus (HPV) Testing Market?

Major players include Roche Diagnostics, Abbott Laboratories, Hologic Inc., Qiagen, and Thermo Fisher Scientific.